Remus Pharmaceuticals Profit & Loss Annual

BSE: - | NSE: - | ISIN: - | Sector: -

796.95 +32.15 (4.20%)Updated : 18 Jun 2026

Interim Data

Annual Data

Fiscal Period	2026	2025	2024	2023
Period End Date	Mar 26	Mar 25	Mar 24	Mar 23
Total Operating Expense	799.68	576.54	185.59	34.96
Other Net	6.68	0.86	0.89	0.46
Diluted Weighted Average Shares	0.94	1.18	1.13	0.82
Depreciation/ Amortization	2.76	1.87	0.90	0.48
Operating Income	53.95	43.82	26.91	10.07
Net Income	36.99	29.07	21.54	8.50
Income Availableto Com Excl Extra Ord	36.99	29.07	21.54	8.50
Other Operating Expenses Total	41.89	0.39	0.02	0.00
Net Income Before Taxes	59.16	47.34	31.83	11.41
Minority Interest	-9.18	-9.35	-4.44	-
Net Income After Taxes	46.17	38.42	25.98	8.50
Income Availableto Com Incl Extra Ord	36.99	29.07	21.54	8.50
Costof Revenue Total	742.21	532.87	164.33	21.44
Gross Profit	111.42	87.49	48.17	23.59
Interest Inc( Exp) Net- Non- Op Total	-1.47	2.45	2.51	0.89
Diluted Net Income	36.99	29.07	21.54	8.50
DPS- Common Stock Primary Issue	1.00	1.00	0.75	0.25
Provisionfor Income Taxes	12.99	8.92	5.85	2.91
period Type	-	-	-	-
Net Income Before Extra Items	36.99	29.07	21.54	8.50
Total Revenue	853.63	620.36	212.50	45.03
period Length	12.00	12.00	12.00	12.00
Revenue	853.63	620.36	212.50	45.03
Selling/ General/ Admin Expenses Total	12.82	41.41	20.35	13.02
Diluted Normalized EPS	39.19	24.52	17.91	10.42
Diluted EPS Excluding Extra Ord Items	39.19	24.67	19.00	10.41
Gain( Loss)on Saleof Assets	-	0.21	1.51	-
Unusual Expense( Income)	-	-	-	0.02

*All figures in crores except per share values

Trending Stocks

2,991.00+94.00(3.24%)

261.55+8.00(3.16%)

1,469.45+23.35(1.61%)

390.15-3.45 (-0.88%)

352.80-2.65 (-0.75%)

Related News